Maybe your friend swears by it. Maybe you’ve tried it. Or just want to. For aches and pains. For worries and late nights. For your loved ones, your dog or your bum knee.
is your independent guide to hemp-derived cannabinoid wellness. Using laboratory testing, data algorithms and a world class Advisory Board of scientists and MDs, we lab test and analyze every product we sell. We tell you what you need to know, then make available the products that are exceptional.
Learn why only 20% of the products we test pass our stringent standards.
Third party laboratories conduct ultra high performance liquid chromatography (UHPLC) testing. Testing specifically for the psychoactive compound THC ensures compliance with the 2018 United States Farm Bill that all products contain less than 0.3% THC.
The TruPotency Science Team has developed a database of relevant cannabinoids, terpenes and other key ingredients and assigned a score for each product based on their contents. The TruPotency algorithm uses these scores to determine which products are right for you.
Our Science Advisory Board -- PhDs and MDs, as well as our staff professionals have decades of experience in the cannabis industry that we use to vet all of our products.
Adam Friedman, MD, FAAD is Professor and Interim Chair of Dermatology and serves as Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences. Dr. Friedman is currently investigating novel nanotechnologies that allow for controlled and sustained delivery of a wide spectrum of physiologically and medicinally relevant molecules, such as cannabinoids, with an emphasis on treating infectious diseases, accelerating wound healing, immune modulation, and correcting vascular dysfunction.
He holds multiple patents derived from these investigations, and has published over 170 papers/chapters and 2 textbooks on both his research as well as a variety of clinical areas in dermatology with an emphasis on emerging medical therapies. He has received multiple awards such as the American Dermatologic Association Young Leader Award, the American Society for Dermatologic Surgery Cutting Edge Research Award, the 2017 Elle Beauty Genius Award, and has been on the Washingtonian Top Doctors list since 2017.
PhD in Plant Science
Dr. Hope Jones is Chief Scientific Officer of Emergent Cannabis Sciences — a research, development and advising company — whose mission is to drive scientific innovation within the cannabis industry. And formally Chief Scientific Officer for C4 Laboratories — a research, advanced analysis and characterization of cannabis medicine company. She is a graduate of the University of Arizona's Controlled Environment Agriculture Center (CEAC) where she worked to propagate endangered native species using tissue culture techniques. And she is one of a very select few scientists in this country that have extensive experience in utilizing these techniques with cannabis specifically.
Dr. Jones' previously worked as a Staff Scientist for NASA’s Life Sciences and Biosystems Engineering Program, where she was responsible for micropropagation production of crops high in antioxidants, phytochemical research and developing growing system technologies that improved both quality and quantity of crop yields during deep space missions. Dr. Jones has also worked as the Director of Science and Micropropagation for a large cannabis cultivation and product manufacturer in Arizona and has been apart of many matters of local importance to cannabis policy and reform - including, drafting legislation in Arizona to implement the recently passed Hemp and testing bills.
PhD in Pharmacology
Dr. Vanderah is Head and Professor of Pharmacology, and is a Professor in the Departments of Neurology and Anesthesiology at The University of Arizona, College of Medicine, in Tucson. His research interests include mechanisms of cancer pain, neuronal integration in pain pathways, neurochemical release during conditions of neuropathy, neuronal plasticity, addiction, cannabinoid & opioid receptor pharmacology, as well as the discovery of novel targets for new medications.
His recent research details how select cannabinoids can act synergistically with opioids to inhibit chronic pain while blocking the opioid-induced rewarding behavior and decrease opioid-induced respiratory depression. Studies include investigation of selective cannabinoids in chronic administration and cognitive function. He is the Principle Investigator on multiple research grants, has authored over 170 original research articles, 3 Human Neuroscience books and 1 Pharmacology book. He has taught in the medical school for over 20 years and earned over 25 teaching awards.
Director of Science for TruPotency
Austin Flohrschutz is the Director of Science for TruPotency. He holds a Masters of Science degree in Neuroscience from the University of Arizona, and a B.S. in Behavioral Neuroscience from the University of Kansas. Austin has worked in a broad variety of research laboratories - first in social psychology, then cognitive neuroscience and finally medicinal chemistry. Austin focused on extracting biologically active compounds from plants, which were then purified and used to synthesize new potential drugs to treat pain without addictive properties.
Less than 30% of CBD Products Are Accurately Labeled
On December 19th, 2019, Austin held this successful IAma (Ask Me Anything) Forum on Reddit, which generated over 40,000 upvotes.
A trailblazing corporate paradigm buster who digitized Estee Lauder and e-commed cosmetics. Moving from beauty to wellness is a natural progression for her and the customers she’s led for so long. Generationally refreshing and relatable.
A young entrepreneur. CannaCribs creator & host. Founder of GrowersHouse. Far from a weed-bro, Nate represents curiosity, thoroughness and high performance. Professional and accessible, he de-stigmatizes in what he does and how he does it.